Taken together, our results demonstrated that the miR‐23a‐STAT5A‐AKT signaling pathway is critical to alter glucose metabolism in HCC and may offer new opportunities for effective therapy. This evidence concerns the gene AKT1 and hepatocellular carcinoma.